Workflow
Securities Fraud
icon
Search documents
Class Action Reminder for KMX Investors: Kessler Topaz Meltzer & Check, LLP Reminds CarMax, Inc. (KMX) Investors of Securities Fraud Class Action Lawsuit
Globenewswire· 2025-11-20 19:44
RADNOR, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that an amended securities class action lawsuit has been filed against CarMax, Inc. (“CarMax”) (NYSE: KMX) which expands the class period to include those who purchased or otherwise acquired CarMax securities between June 20, 2025, and November 5, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is January 2, 2026. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If ...
Attention Long-Term Shareholders of Inspire Medical Systems, Inc. (INSP): Grabar Law Office is Investigating Claims on Your Behalf
Newsfile· 2025-11-20 18:55
Attention Long-Term Shareholders of Inspire Medical Systems, Inc. (INSP): Grabar Law Office is Investigating Claims on Your BehalfNovember 20, 2025 1:55 PM EST | Source: Grabar Law OfficePhiladelphia, Pennsylvania--(Newsfile Corp. - November 20, 2025) - Grabar Law Office is investigating claims on behalf of Inspire Medical Systems, Inc. (NYSE: INSP) shareholders. The investigation concerns whether certain officers of Inspire Medical have breached their fiduciary duties owed to the company.Curr ...
NASDAQ: VRNS Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Varonis Systems, Inc. (NASDAQ: VRNS) Investors with Significant Losses to Contact the Firm
Globenewswire· 2025-11-20 15:15
Core Viewpoint - Varonis Systems, Inc. reported disappointing financial results for Q3 2025, leading to a significant decline in stock price and prompting an investigation into potential violations of federal securities laws [2][1]. Financial Performance - Varonis reported a revenue miss against consensus estimates, with a notable 63.9% year-over-year decline in term license subscription revenues [2]. - The company reduced its full-year Annual Recurring Revenue (ARR) guidance due to underperformance in its on-premises subscription business, which was identified as a drag on overall ARR growth [2]. Stock Market Reaction - Following the announcement of poor financial results, Varonis' stock price plummeted by $30.66 per share, or 48.67%, closing at $32.34 per share on October 29, 2025 [2]. Investigation - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of Varonis investors [1].
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zions Bancorporation, N.A. - ZION
Prnewswire· 2025-11-20 15:00
Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Zions Bancorporation and its officers or directors [1][2]. Group 1: Company Financials - On October 15, 2025, Zions announced a $50 million charge-off related to a loan from its subsidiary, California Bank & Trust, due to "apparent misrepresentations and contractual defaults by the Borrowers and Obligors and other irregularities" [2]. - Following this announcement, Zions' stock price dropped by $7.10 per share, or 13.14%, closing at $46.93 per share on October 16, 2025 [2]. Group 2: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is leading the investigation into Zions Bancorporation [3]. - The firm has a history of recovering significant damages for victims of securities fraud and corporate misconduct [3].
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkami Technology, Inc. - ALKT
Prnewswire· 2025-11-20 15:00
Core Insights - Alkami Technology, Inc. is under investigation for potential securities fraud and unlawful business practices [1] - The company reported third-quarter 2025 financial results, with GAAP earnings per share of -$0.14, missing estimates by $0.02, and revenue of $113 million, missing estimates by $0.48 million [2] - Following the earnings report, Alkami's stock price dropped by $1.70, or 7.73%, closing at $20.29 per share [2] Company Financial Performance - For Q3 2025, Alkami reported a GAAP earnings per share of -$0.14, which was below the consensus estimate by $0.02 [2] - The revenue for the same quarter was $113 million, falling short of consensus estimates by $0.48 million [2] Stock Market Reaction - The announcement of the financial results led to a decline in Alkami's stock price by $1.70, representing a 7.73% decrease [2]
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bitdeer Technologies Group - BTDR
Prnewswire· 2025-11-20 15:00
Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Bitdeer Technologies Group regarding potential securities fraud or unlawful business practices [1] Financial Performance - Bitdeer reported unaudited financial results for Q3 2025, with earnings per share of -$1.28, significantly missing the consensus estimate of -$0.22 [2] - Following the earnings report, Bitdeer's stock price fell by $2.63 per share, or 14.9%, closing at $15.02 on November 11, 2025 [2] Operational Issues - Bitdeer disclosed a significant delay in the development of its next-generation Seal 04 ASIC chip [2] - A fire incident occurred at Bitdeer's under-construction facility in Massillon, Ohio, damaging 2 of the 26 buildings [2] - The stock price dropped further by $2.83 per share, or 20.3%, closing at $11.11 on November 13, 2025, following the fire incident [2]
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC
Prnewswire· 2025-11-20 15:00
Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Regencell Bioscience Holdings Limited and its officers or directors [1][2]. Group 1: Investigation Details - Regencell disclosed on October 31, 2025, that it received a subpoena from the U.S. Department of Justice (DOJ) regarding an investigation into trading of its Ordinary Shares [2]. - The DOJ has requested documents and communications related to corporate operational, financial, and accounting matters [2]. - Regencell anticipates incurring significant legal costs and may face fines or penalties exceeding its insurance coverage due to the investigation [2]. Group 2: Market Reaction - Following the announcement of the DOJ investigation, Regencell's stock price dropped by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025 [2].
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beyond Meat, Inc. - BYND
Prnewswire· 2025-11-20 15:00
Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices by Beyond Meat, Inc. and its officers or directors, following significant stock price declines related to impairment charges and delayed earnings announcements [1][2]. Group 1: Company Financial Issues - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to long-lived assets, which was anticipated to be material [2]. - Following this announcement, Beyond Meat's stock price dropped by $0.655 per share, or 23.06%, closing at $2.185 per share on the same day [2]. - On November 3, 2025, the company delayed its third-quarter earnings announcement, citing the need for additional time to complete the impairment review, resulting in a further stock price decline of $0.275 per share, or 16.52%, closing at $1.39 per share [2]. Group 2: Legal Investigation - Pomerantz LLP, a firm recognized for its work in corporate and securities class litigation, is leading the investigation into Beyond Meat's practices, emphasizing its long history of fighting for victims of securities fraud and corporate misconduct [3].
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zimmer Biomet Holdings, Inc. - ZBH
Prnewswire· 2025-11-20 15:00
Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Zimmer Biomet and its executives [1] - Zimmer Biomet reported third-quarter 2025 net sales of $2 billion, which fell short of the consensus estimate of $2.01 billion [2] - The company revised its full-year organic revenue growth outlook down to a range of 3.5% to 4%, from a previous range of 3.5% to 4.5% [2] - Weakness in international markets and non-core businesses, along with order cancellations in the Middle East and Eastern Europe, negatively impacted results [2] - The stock price of Zimmer Biomet dropped by $15.63 per share, or 15.5%, closing at $87.55 on November 5, 2025, following the earnings announcement [2]
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Owens Corning - OC
Prnewswire· 2025-11-20 15:00
Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Owens Corning and its officers/directors following a significant financial loss reported in Q3 2025 [1][2]. Financial Performance - Owens Corning reported a net loss of $495 million, or $5.93 per diluted share, for Q3 2025, a stark contrast to a net income of $287 million, or $3.26 per share, in the same period of 2024 [2]. - The loss was primarily attributed to a $780 million non-cash impairment charge related to the Company's doors business [2]. - The Company anticipates a decline in revenue for Q4 2025, projecting between $2.1 billion and $2.2 billion due to soft residential markets and reduced demand for storm-related roofing [2]. Market Reaction - Following the announcement of the financial results, Owens Corning's stock price fell by $11.69 per share, or 9.53%, closing at $111.03 per share on November 5, 2025 [2].